Dei Cas L, Manca C, Bernardini B, Vasini G, Visioli O
J Cardiovasc Pharmacol. 1982 May-Jun;4(3):436-40. doi: 10.1097/00005344-198205000-00014.
We investigated the effect of oral ibopamine (SB 7505) on myocardial and renal function in eight patients suffering from congestive heart failure. Ibopamine was administered orally 50 mg twice a day for 7 days. Systolic time intervals PEP (preejection period) and EMS (electromechanical systole) decreased significantly after each administration of ibopamine. Maximum reduction of systolic time intervals was observed 4 h after ibopamine administration. Statistically significant shortening was still apparent at 8 h. Twenty-four hour urinary volume was greater than control values on each day of ibopamine administration. The average daily increase in urine output was 70.2%. Sodium and potassium excretion increased. Each patient showed symptomatic improvement during therapy. No side effects attributed to ibopamine therapy were observed, and clinical laboratory values were unchanged. Tachyphylaxis was not observed during the period of treatment. We conclude that oral administration of ibopamine improves cardiovascular performance and renal function in patients with congestive heart failure.
我们研究了口服异波帕明（SB 7505）对8例充血性心力衰竭患者心肌和肾功能的影响。异波帕明口服剂量为50毫克，每日两次，共7天。每次服用异波帕明后，收缩期时间间期PEP（射血前期）和EMS（机电收缩期）均显著缩短。服用异波帕明4小时后观察到收缩期时间间期的最大缩短。8小时时仍有统计学意义的缩短。在服用异波帕明的每一天，24小时尿量均大于对照值。尿量平均每日增加70.2%。钠和钾排泄增加。每位患者在治疗期间症状均有改善。未观察到异波帕明治疗引起的副作用，临床实验室值未改变。治疗期间未观察到快速耐受性。我们得出结论，口服异波帕明可改善充血性心力衰竭患者的心血管功能和肾功能。
